|
KR20200069316A
|
|
Semaglutide in medical therapy
|
|
KR20180100177A
|
|
EGF (A) analogs with fatty acid substituents
|
|
KR20160065126A
|
|
Novel derivative of an insulin analogue
|
|
KR20160029079A
|
|
Derivatives of glp-1 like peptides, and uses thereof
|
|
KR20180137614A
|
|
Human cd30 ligand antigen binding proteins
|
|
KR20200013078A
|
|
Compositions of glp-1 peptides and preparation thereof
|
|
KR20140037918A
|
|
Selective elimination of erosive cells
|
|
KR20190045393A
|
|
Double-acylated glp-1 derivatives
|
|
KR20130092972A
|
|
Process for the preparation of insulin-zinc complexes
|
|
KR20160124929A
|
|
Protease stabilized, acylated insulin analogues
|
|
KR20120026629A
|
|
Novel insulin derivatives
|
